Aligos Therapeutics, Inc.
ALGS
$7.37
-$0.28-3.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1,574.56% | -77.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,574.56% | -77.19% | |||
| Cost of Revenue | -96.09% | -28.82% | |||
| Gross Profit | 112.83% | 27.28% | |||
| SG&A Expenses | 29.57% | -4.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.37% | -24.46% | |||
| Operating Income | -23.45% | 23.08% | |||
| Income Before Tax | -14.47% | 36.94% | |||
| Income Tax Expenses | 956.67% | -46.43% | |||
| Earnings from Continuing Operations | -15.89% | 36.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.89% | 36.96% | |||
| EBIT | -23.45% | 23.08% | |||
| EBITDA | -23.31% | 23.40% | |||
| EPS Basic | -15.68% | 37.05% | |||
| Normalized Basic EPS | -14.26% | 37.03% | |||
| EPS Diluted | -15.53% | 36.96% | |||
| Normalized Diluted EPS | -14.26% | 37.03% | |||
| Average Basic Shares Outstanding | 0.19% | 0.14% | |||
| Average Diluted Shares Outstanding | 0.19% | 0.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||